Carregant...

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer

HER2-positive (HER2+) breast cancer accounts for 18%–20% of all breast cancer cases and has the second poorest prognosis among breast cancer subtypes. Trastuzumab, the first Food and Drug Administration-approved targeted therapy for breast cancer, established the era of personalized treatment for HE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biochim Biophys Acta
Autors principals: Vu, Thuy, Sliwkowski, Mark X., Claret, Francois X.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4261073/
https://ncbi.nlm.nih.gov/pubmed/25065528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbcan.2014.07.007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!